In early 2020, as the COVID-19 pandemic reshaped our world, Medialis Ltd recognised the urgent need for a disease-specific quality of life (QoL) instrument for long COVID patients. This, led to the development of the PAC-19QoL.
Rapid Development Timeline: We received ethical approval in October 2020 and initiated the development of the PAC-19QoL on November 23, 2020. The PAC-19QoL was completed in just 27 days, finalising it on December 20, 2020.
Validation and Publication: The PAC-19QoL was validated on December 29, 2020, and our findings were published in September 2021. For a comprehensive understanding of our work, you can read the full publication here: https://lnkd.in/dPRV3XdS
Unique and Reliable Outcome Measure: To the best of our knowledge, the PAC-19QoL is the only validated outcome measure for Long COVID. Our PAC19QoLReg registry (NCT04586413), established to gather data, has confirmed the instrument’s reliability in predicting long-term outcomes and assessing patient variation from baseline.
Interested in developing disease-specific instruments? Contact us at info@medialis.co.uk to learn how we can assist you. Together, let’s continue to innovate and improve patient outcomes!
#MedialisLtd #PAC19QoL #LongCOVID #QualityOfLife #DiseaseSpecific #Pandemic #COVID19
Link: https://www.linkedin.com/feed/update/urn:li:ugcPost:7225115706663555072/?actorCompanyId=11809093